指南与共识食管胃疾病与幽门螺杆菌

白皮书 AGA:嗜酸性粒细胞性食管炎的药物研发

White Paper AGA: Drug Development for Eosinophilic Esophagitis.
指南 / 共识 · Clin Gastroenterol Hepatol · 2017-03-22

本文基于2016年美国胃肠病学会诊断与治疗中心主办的药物研发会议,总结嗜酸性粒细胞性食管炎(EoE)药物研发的讨论。文章指出尽管多种饮食、药物及内镜治疗有效,但尚无获FDA或欧洲监管机构批准者;诊断标准演变、与胃食管反流病(GERD)的复杂交互、临床表现异质性及治疗终点争议均阻碍试验设计。

要点

  • EoE自20世纪90年代初被认识以来,已成为儿童和成人食管症状的常见病因。
  • 多种饮食、药物及内镜治疗有效,但FDA和欧洲监管机构均未批准任何药物。
  • 诊断标准演变、与GERD的复杂交互及治疗终点争议阻碍了临床试验设计。

核心结论

  • 尽管研究者、产业界、FDA和患者倡导组织合作推动EoE药物研发取得实质性进展,但诊断标准演变、与GERD的交互、临床表现异质性及治疗终点争议仍构成挑战。

研究设计与样本

  • 本文为美国胃肠病学会(AGA)诊断与治疗中心赞助的2016年药物研发会议基础上对EoE讨论的总结。

主要发现

  • EoE自20世纪90年代初2个小型病例系列首次描述以来,已成为儿童和成人食管症状的常见病因。
  • 多种饮食、药物及内镜治疗有效,但目前FDA和欧洲监管机构均未批准任何药物。
  • 诊断标准演变、与GERD的复杂交互、临床表现异质性及治疗终点争议阻碍了药物研发和临床试验设计。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since first characterized in 2 small case series in the early 1990s, eosinophilic esophagitis (EoE) has emerged as a commonly identified cause of esophageal symptoms in children and adults.1,2 Although several highly effectively dietary, pharmacologic, and endoscopic therapies have been reported, none is currently approved by either the US Food and Drug Administration (FDA) or European regulatory authorities. Evolving diagnostic criteria have challenged drug development, in particular the recognition of complex interactions with the most prevalent esophageal disorder, gastroesophageal reflux disease (GERD). Heterogeneity in the clinical presentations of affected children and adults has created difficulties with uniform inclusion criteria and the development of disease-specific, patient-reported outcome (PRO) instruments. Furthermore, controversies regarding the appropriate therapeutic endpoints of EoE have impeded the design of clinical trials. Despite these obstacles, collaborative efforts by investigators, industry, the FDA, and patient advocacy groups have resulted in substantial progress in drug development in EoE over the past 2 decades.3 The purpose of this article is to summarize discussions on EoE based on the 2016 Drug Development Conference sponsored by the Center for Diagnostics and Therapeutics of the American Gastroenterological Association.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Hirano I, Spechler S, Furuta G, et al. White Paper AGA: Drug Development for Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2017. PMID: 28342955. doi:10.1016/j.cgh.2017.03.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。